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Abstract
Background: The elevated expression of vascular endothelial growth factor C (VEGF-C) is correlated with clinical 
cervical cancer metastasis and patient survival, which is interpreted by VEGF-C functions to stimulate angiogenesis and 
lymphatic genesis. However, the direct impact of VEGF-C on cervical cancer cell motility remains largely unknown.
Methods: In this study, we investigated the effects of VEGF-C on actin cytoskeleton remodeling and on cervical cancer 
cell migration and invasion and how the actin-regulatory protein, moesin regulated these effects through RhoA/ROCK-
2 signaling pathway.
Results: On cervical carcinoma cell line SiHa cells, exposure of VEGF-C triggered remodeling of the actin cytoskeleton 
and the formation of membrane ruffles, which was required for cell movement. VEGF-C significantly enhanced SiHa 
cells horizontal migration and three-dimensional invasion into matrices. These actions were dependent on increased 
expression and phosphorylation of the actin-regulatory protein moesin and specific moesin siRNA severely impaired 
VEGF-C stimulated-cell migration. The extracellular small GTPase RhoA/ROCK-2 cascade mediated the increased 
moesin expression and phosphorylation, which was discovered by the use of Y-27632, a specific inhibitor of Rho kinase 
and by transfected constitutively active, dominant-negative RhoA as well as ROCK-2 SiRNA. Furthermore, in the surgical 
cervical specimen from the patients with FIGO stage at cervical intra-epithelial neoplasia and I-II cervical squamous cell 
carcinoma, the expression levels of moesin were found to be significantly correlated with tumor malignancy and 
metastasis.
Conclusions: These results implied that VEGF-C promoted cervical cancer metastasis by upregulation and activation of 
moesin protein through RhoA/ROCK-2 pathway. Our findings offer new insight into the role of VEGF-C on cervical 
cancer progression and may provide potential targets for cervical cancer therapy.
Background
Cervical cancer is the second most common cancer in
women worldwide and it has been steadily increasing in
young women [1]. Human papillomavirus (HPV) infec-
tion causes virtually all cases of cervical cancer. Recent
years the great advancement of prophylactic vaccines
which aim directly at different types of HPV has been
achieved and results in a substantial reduction in the inci-
dence of cervical cancer [2]. Notwithstanding, many
issues related to the radical therapy of existing cervical
cancer remain unresolved. One major problem is the cer-
vical cancer metastasis, which is the leading cause of
mortality.
Cancer metastasis is composed of a complex series of
phenotypic and biochemical changes such as angiogene-
sis, lymphangiogenesis, gene expression, motility or cell
shape. These alterations are regulated by several sets of
growth factors and their cognate receptors [3]. Vascular
endothelial growth factor C (VEGF-C), a dimeric glyco-
protein belonging to VEGF family of cytokines, is found
to be implicated in the most aggressive tumors. By bind-
ing to its receptor Flt-4, VEGF-C promotes angiogenesis
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and/or lymphangiogenesis, thus accelerates cancer
metastasis to lymph nodes and distant organs [4,5]. Cor-
respondingly, clinical studies have verified that VEGF-C
expression is closely related to invasion phenotype and
affects the patient's survival in cervical carcinomas [6-8].
Previously, it was reported that the Flt-4 expression was
restricted in the endothelial cells of lymphatic vessels.
Recent years the Flt-4 has been shown to be expressed in
a variety of human malignancies, including cervical can-
cer [9,10]. These observations hint the possibility that as
the specific ligand to Flt-4, VEGF-C may be implicated in
cervical cancer progression by direct impacts on tumor
cells.
Cell migration is critical to cancer cell invasion and
metastasis. The first step is represented by dynamic fila-
mentous actin cytoskeletal remodeling, which allows the
formation of protrusions that adhere to the extra-cellular
matrix and generate intra-cellular forces for cell move-
ment [11,12]. Indeed, actin remodeling is involved in can-
cer transformation and metastasis [13]. Our previous
work indicated that actin remodeling is the primary step,
n o t  o n l y  f o r  c a n c e r  c e l l  m e t a s t a s i s  [ 1 4 ] ,  b u t  a l s o  f o r
endothelial and neuron cell migration [15,16]. These
events are mediated by moesin, an actin-binding protein
belonging to the ezrin/radixin/moesin (ERM) family.
Indeed, moesin gene expression is shown to be strongly
associated with metastatic phenotypes of cervical cancer
[17]. There is also evidence showing that VEGF-C
enhances cervical cancer cell motility [10], but the under-
lying mechanisms remain largely unknown. In the pres-
ent study, we purpose to investigate the effects of VEGF-
C on actin cytoskeleton remodeling and on cervical can-
cer cell migration and to characterize the role of moesin
and the signaling cascade implicated in these actions.
Methods
Cell cultures and treatments
An established cervical carcinoma cell line (SiHa) was
used for this study. SiHa cells were incubated in RPMI
1640 medium containing 10% fetal calf serum (FCS), L-
glutamine and penicillin streptomycin under a 5% CO2
atmosphere at 37°C. An inhibitor was always to be added
1 h before starting the treatments. Recombinant human
VEGF-C wild type (2179-VC-025) and the fusion protein
of human IgG with the extracellular ligand-binding
domains of Flt-4 (Flt-4/IgG) (349-F4-050) were pur-
chased from R&D Systems (Minneapolis, MN). The
selective inhibitor of the Rho-associated protein kinase Y-
27632 was from Sigma-Aldrich (Saint-Louis, MO).
Immunoblottings
Cell lysates were separated by SDS-PAGE. Antibodies
used were: moesin (clone 38, Transduction Laboratories,
Lexington, KY), Thr558-P-moesin (sc-12895, Santa Cruz
Biotechnology, Santa Cruz, CA), RhoA (sc-418, Santa
Cruz), ROCK-2 (sc-5561, Santa Cruz), β-actin (sc-1615,
Santa Cruz). Primary and secondary Abs were incubated
with the membranes with standard technique. Immuno-
detection was accomplished using enhanced chemilumi-
nescence. Chemiluminescence was acquired with a
quantitative digital imaging system (Quantity One, Bio-
Rad, Hercules, CA) allowing to check for saturation. Den-
sitometry values were adjusted to β-actin intensity and
normalized to expression level from the control sample.
Kinase assays
SiHa cells were harvested in 20 mM Tris-HCl, 10 mM
EDTA, 100 mM NaCl, 0.5% IGEPAL and 0.1 mg/mL
PMSF. Equal amounts of cell lysates were immunoprecip-
itated with 40 μg Rhotekin RBD agarose (14-383, upstate)
vs. GTP-RhoA or an Ab vs. ROCK-2 (sc-5561, Santa
Cruz). The IPs were washed three times with buffer con-
taining 20 mM Tris-HCl, 10 mM EDTA, 150 mM NaCl,
0.1% IGEPAL and 0.1 mg/mL PMSF. For ROCK-2 activity
assay, two additional washes were performed in kinase
assay buffer (20 mM MOPS, 25 mM b-glycerophosphate,
5 mM EGTA, 1 mM DTT) and the samples were there-
fore resuspended in this buffer. 5 mg of de-phosphory-
lated myelin basic protein (Upstate) together with 500
mM ATP and 75 mM MgCl2 were added to each sample
and the reaction was started at 30°C for 20 min. The reac-
tion was stopped on ice and the samples were resus-
pended in Laemmli Buffer. The samples were separated
with SDS-PAGE and Western blot analysis was per-
formed using antibodies recognizing RhoA (sc-418, Santa
Cruz) or Thr98-P-myelin basic protein (05-429, Upstate).
Cell immunofluorescence
SiHa cervical cancer cells were grown on coverslips and
exposed to treatments. Cells were fixed with 4% para-
formaldehyde for 30 min and permeabilized with 0.1%
Triton X for 5 min. Blocking was performed with 3% nor-
mal serum for 20 min. After washing the nuclei were
counterstained with 4'-6-diamidino-2-phenylindole
(DAPI) (Sigma) and actin was stained with Texas Red-
phalloidin (Sigma). The coverslips were mounted with
Vectashield mounting medium (Vector Laboratories,
Burlingame, CA). Immunofluorescence was observed by
an Olympus BX41 microscope and images were captured
by DP70 Olympus digital camera with high-resolution.
Transfection experiments
Each plasmid (15 μg) was transfected into SiHa cervical
cancer cells using the Lipofectamine (Invitrogen) accord-
ing to the manufacturer's instructions. Plasmids contain-
ing RhoA T19 and RhoA G14V were transfected. These
constructs were obtained from the Guthrie cDNA
Resource Center http://www.cdna.org. As control, paral-He et al. BMC Cancer 2010, 10:170
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lel cells were transfected with empty pcDNA3.1+ plasmid
(mock-transfected). After transfection for 24 h, cells (60-
70% confluent) were treated with VEGF-C (100 ng/mL)
for 48 h and cellular extracts were prepared according to
the experiments to be performed.
Moesin on-target plus siRNA (J-011772-06), ROCK-2
siGENOME SMARTpool siRNA (L-004610-00) and
scrambled control siRNA (D-001810-01) were obtained
from Dharmacon. SiHa cells (40% confluent) were serum-
starved for 1 h followed by incubation with 100 nM target
siRNA or control siRNA (scrambled siRNA) for 6 h in
serum-free media. The serum-containing media was then
added (10% serum final concentration) for 42 h before
experiments and/or functional assays were conducted.
Target protein silencing was assessed through protein
analysis up to 48 h after transfection.
Cell migration assays
Cell migration was assayed with razor scrape assays as we
previously described [14]. Briefly, a razor blade was
pressed through the confluent SiHa cervical cancer cell
monolayer into the plastic plate to mark the starting line.
Cells were swept away on one side of that line. Cells were
washed, and 2.0 mL of RPMI 1640 containing steroid-
deprived FBS and gelatin (1 mg/mL) were added. Migra-
tion was monitored for 48 hours. Fresh medium and
treatment were replaced every 12 h. Cells were digitally
imaged and migration distance was measured by phase-
contrast microscopy.
Cell invasion assays
As we previously described [14], cell invasion were
assayed following the standard method by using the BD
BioCoat™ Growth Factor Reduced (GFR) Matrigel™ Inva-
sion Chamber (BD Bioscience, USA). In brief, after rehy-
drating the GFR Matrigel inserts, the test substance was
added to the wells. An equal number of Control Inserts
(no GFR Matrigel coating) were prepared as control. 0.5
mL of SiHa cell suspension (2.5 × 104 cells/mL) was added
to the inside of the inserts. The chambers were incubated
for 48 h at 37°C, 5% CO2 atmosphere. After incubation,
the non-invading cells were removed from the upper sur-
face of the membrane using cotton tipped swabs. Then
the cells on the lower surface of the membrane were
stained with Diff-Quick stain. The invading cells were
observed under the microscope at 100 × magnification.
Cells were counted in the central field of triplicate mem-
branes. The invasion index was calculated as the % inva-
sion test cell/% invasion control cell.
Patients, specimens, and immunohistochemical staining
Tissues were from cervical cancer patients hospitalized in
the first hospital of Sun Yat-sen University (Guangzhou,
China) with informed patient consent, including 24
patients with cervical intra-epithelial neoplasia (CIN), 22
patients with squamous carcinoma at stage I, and 20
patients with squamous carcinoma at stage II without
radiotherapy or chemotherapy. The histological diagnosis
was made according to the International Federation of
Gynecology and Obstetrics (FIGO) staging system.
Lymph node status was evaluated. Tissues from the nor-
mal cervix of 20 patients suffering from hysteromyoma
who were undergone hysterectomy were taken as the
control. All tissues were stored at -80°C until use.
Immunohistochemical staining was performed as we
previously described [18]. Histological sections of 4 μm
were mounted on silanized slides and allowed to dry for 1
h at room temperature (RT), followed by 1 h incubation
in an oven at 60°C. Briefly, after deparaffination and rehy-
dration, epitope retrieval was performed by immersing
slides in DAKO Epitope Retrival Solution (0.01 M citrate
buffer, pH 6.0) in a water bath at 98°C for 40 minutes fol-
lowed by a 20 minutes cool-down period at room temper-
ature (RT). The working dilution for the anti-human
moesin monoclonal antibody (clone 38, Transduction
Laboratories, Lexington, KY) was 1:50. The sections were
incubated with primary antibodies at RT for 1 hour.
Expression of moesin was evaluated according to the
ratio of positive cells per specimen and staining intensity
as described previously [19]. The ratio of positive cells
per specimen was evaluated quantitatively and scored 0
for staining of ≤ 1%, 1 for staining of 2 to 25%, 2 for stain-
ing of 26 to 50%, 3 for staining of 51 to 75%, and 4 for
staining ≥ 75% of the cells examined. Intensity was graded
as follows: 0, no signal; 1, weak; 2, moderate; and 3, strong
staining. A total score of 0 to 12 was finally calculated and
graded as negative (-; score: 0-1), weak (+; 2-4), moderate
(++; 5-8), and strong (+++; 9-12).
Statistical analysis
Values are expressed as mean ± SD. Statistical differences
between mean values were determined by ANOVA, fol-
lowed by the Fisher's protected least significance differ-
ence (PLSD). To compare the differences of groups for
immunohistochemistry, Kruskal Wallis Test and Chi-
Square Test were used to calculate the P value. All differ-
ences were considered significant at P < 0.05.
Results
VEGF-C promoted SiHa cell migration and invasion and 
provoked actin cytoskeleton remodeling
First we observed the direct impact of VEGF-C on SiHa
cell migration and invasion. As shown in Fig. 1A-B, the
stimulation with VEGF-C (100 ng/mL) for 24 or 48 h
showed increased number of cells migrating across the
starting line, as compared to the control. Consistently, the
number of cells that invaded the matrix with the treat-
ment of VEGF-C (100 ng/mL) for 24 or 48 h in the insertsHe et al. BMC Cancer 2010, 10:170
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with GFR Matrigel was much higher than that in the con-
trol, as indicated by the value of invasion indexes (Fig.
1C).
It is well known that actin cytoskeleton remodeling is
the initial step for cell migration and invasion. Therefore,
we studied the effect of VEGF-C on actin rearrangement.
At baseline, actin fibers in SiHa cell were arranged longi-
tudinally in the cytoplasm and the cell membrane was
regular (Fig. 1D). Treatment with VEGF-C (100 ng/mL)
up to 12 h led to the shift of the actin fibers toward the
edge of the membrane, in association with the formation
of specialized membrane structures like filopodia, pseu-
dopodia and focal adhesion complexes (Fig. 1D). These
changes on actin organization could be observed in a
majority of SiHa cells (about 75% of total cells). Flt-4/IgG
is the fusion protein of human IgG with the extracellular
ligand-binding domains of Flt-4. It competitively binds
available VEGF ligands and, therefore, blocks respective
VEGF activity by interfering with ligand-receptor interac-
tions [20]. The Flt-4/IgG (100 ng/mL) abolished VEGF-
C-induced actin rearrangement (Fig. 1D) in our study,
suggesting that VEGF-C/Flt4 axis played a central role in
these events.
VEGF-C led to activation of the actin-regulatory protein, 
moesin
Next we investigated the effect of VEGF-C on the expres-
sion and phosphorylation of moesin, the protein that
belongs to ERM (ezrin/radixin/moesin) family and regu-
lates actin fibers rearrangement. Indeed, VEGF-C (100
ng/mL) significantly enhanced moesin expression as well
Figure 1 VEGF-C increased SiHa cell migration and invasion and induced actin cytoskeleton remodeling. (A) Cells were treated with VEGF-C 
(100 ng/mL) for 24 or 48 h and cell migration was assayed. SiHa cells were scraped out of the cell culture dish and the extent of migration of the re-
maining cells was assayed. The upper black lines indicate the starting line and the lower black lines indicate the mean migration distance. (B) Migrating 
cell numbers were measured and data representing the migration cell numbers from the starting line are expressed as mean ± SD. * = P < 0.05 vs. 24 
h control; ** = P < 0.01 vs. 48 h control. (C) Cells were treated with VEGF-C (100 ng/mL) for 24 or 48 h. Cell invasion was assayed using invasion cham-
bers. Invading cells were counted in three different central fields of triplicate membranes and invasion indexes are shown. ** = P < 0.01 vs. control. (D) 
SiHa cells were treated with VEGF-C (100 ng/mL) for 6 h, 12 h, 24 h or 48 h alone, or treated with VEGF-C for 48 h in the presence of Flt-4/IgG (100 ng/
mL). Immunofluorescent analysis of Texas Red-phalloidin (in red) revealed the spatial modifications of actin fibres and the formation of specialized cell 
membrane structures. Green, white and yellow arrows indicate lamellipodia, pseudopodia and focal adhesion complexes, respectively. Nuclei were 
counterstained in blue. All the experiments were repeated three times with consistent results, and a representative result is shown.
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as phosphorylation (Fig. 2A, B), which was blocked by
Flt-4/IgG (Fig. 2A, B).
To confirm the role of moesin in VEGF-C-induced
actin cytoskeleton remodeling, we silenced moesin by
using specific siRNA (Fig. 2C: S - Scrambled SiRNA; M -
Moesin SiRNA). As shown in Fig. 2D, the transfection
with moesin siRNA eliminated VEGF-C effect on actin
fibers rearrangement.
VEGF-C activated moesin through RhoA/ROCK-2 pathway
P r e v i o u s l y  w e  h a v e  d e m o n s t r a t e d  t h a t  R h o A / R O C K - 2
cascade is the upstream signaling of moesin activation
[14-16,21]. In line with those findings, here we found that
VEGF-C markedly enhanced total protein expression of
RhoA/ROCK-2 and promoted their activities in SiHa
cells (Fig. 3A-D). These effects were inhibited by Flt-4/
IgG (Fig. 3A-D). Furthermore, blockade of ROCK-2 with
specific inhibitor Y-27632 largely impaired VEGF-C-
induced moesin expression and phosphorylation (Fig. 4A,
B), suggesting the importance of RhoA/ROCK-2 cascade
in VEGF-C-induced moesin expression and activation.
To further test hypothesis of the crucial role of RhoA in
the signaling of VEGF-C/Flt4 axis, moesin expression
was studied with transient transfection of a RhoA consti-
tutively active construct (RhoA CA - RhoA G14V) and a
dominant negative RhoA construct (RhoA DN - RhoA
T 1 9 N ) .  I t  s h o w e d  t h a t  m o e s i n  e x p r e s s i o n  w a s  l i g a n d -
independently enhanced by Rho CA and markedly inhib-
ited by Rho DN (Fig. 4C, D). In parallel, silencing of
ROCK-2 with siRNAs prevented the VEGF-C-enhanced
moesin expression (Fig. 5A, B). These results confirmed
Figure 2 VEGF-C led to activation of the actin-regulatory protein, moesin. (A-B) SiHa cells were treated with VEGF-C (100 ng/mL) for 24 or 48 h 
alone, or treated with VEGF-C for 48 h in the presence of Flt-4/IgG (100 ng/mL). Total cell amount of wild-type (Moesin) or Thr558-phosphorylated 
moesin (P-Moesin) or β-actin (Actin) are shown with western blot analysis. Densitometry values were adjusted to β-actin intensity and then normal-
ized to expression from the control sample. ** = P < 0.01 vs. corresponding control. ## = P < 0.01 vs VEGF-C 48 h. (C) SiHa cells were transfected with 
scrambled siRNA (-S) or moesin targeted siRNA (-M) for 48 h. After that the level of moesin expression was detected by western blot as indicated. β-
actin was used as the loading control. (D) SiHa cells were treated with VEGF-C (100 ng/mL) for 48 h, in the presence or absence of scrambled siRNA or 
Moesin siRNA. Cells were stained and analyzed by immunofluorescence. Green, white and yellow arrows indicate lamellipodia, pseudopodia and focal 
adhesion complexes, respectively. All the experiments were repeated three times with consistent results, and a representative result is shown.
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that VEGF-C/Flt4 axis activated moesin by the recruit-
ment of RhoA/ROCK-2 pathway.
RhoA/ROCK-2/moesin cascade was involved in VEGF-C-
enhanced cell migration and invasion
To determine the exact roles of moesin and RhoA/
ROCK-2 signaling implicated in SiHa cell migration and
invasion, we transfected siRNAs against moesin and
ROCK-2 into cells. As expected, both siRNAs dramati-
cally inhibited VEGF-C enhanced-cell migration and
invasion (Fig. 6A, B, C).
The expression levels of VEGF-C and moesin were 
positively correlated with tumor malignancy and 
metastasis
To further examine whether the moesin expression is
altered in cervical cancer, the expression pattern of
moesin were studied in normal cervix and human cervi-
cal cancer tissues by immunohistochemistry. Moesin was
found expressed predominantly in the cytoplasm of nor-
mal and cancer cells. The moesin staining in normal cer-
vical samples (NC) and cervical intraepithelial neoplasia
(CIN) samples was weak, which average staining score
was 2.2 ± 0.92 and 2.6 ± 1.44, respectively (Fig. 7A, B). In
squamous carcinoma at stage I (SC(I)) or II (SC(II)), the
moesin staining was significantly stronger than that of
the NC and CIN samples, which average score was 4.4 ±
1.86 and 6.5 ± 2.63, respectively (Fig. 7A, B).
To investigate if the moesin expression might be associ-
ated with the cervical cancer malignancy or metastasis,
the moesin expression level and the clinicopathologic
characteristics of 42 cervical squamous cancer patients
were compared as summarized in Table 1. These results
provided evidence that high expression of moesin was
Figure 3 VEGF-C activated RhoA/ROCK-2 pathway. (A-B) RhoA expression and its activity were assayed in cells treated with VEGF-C (100 ng/mL) 
for 24 or 48 h alone, or treated with VEGF-C for 48 h in the presence of Flt-4/IgG (100 ng/mL). Active, GTP-bound RhoA was immunoprecipitated with 
Rhoteckin and subsequently assayed with western analysis with an anti-RhoA Ab. ** = P < 0.01 vs. corresponding control; *** = P < 0.001 vs. corre-
sponding control; ## = P < 0.01 vs VEGF-C 48 h. (C-D) ROCK-2 expression and its activity were assayed in cells treated as indicated. ROCK-2 was immu-
noprecipitated with a specific Ab and the IPs were used to phosphorylate the bait protein, myelin basic protein (MBP). ROCK-2 kinase activity is shown 
as the amount of phosphorylated MBP (P-MBP). ** = P < 0.01 vs. corresponding control; ## = P < 0.01 vs VEGF-C 48 h. All the above experiments were 
performed in triplicates and representative images are shown.
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correlated with the malignant grade of cervical cancer (by
Kruskal Wallis Test, X2 = 22.46, P < 0.001) and with the
presence of lymph node metastasis (by Chi-Square Test,
X2 = 15.78, P < 0.01).
Discussion
Cervical cancer is one of the most frequent types of
tumor worldwide and its metastasis is the leading cause
of death in patients with cervical cancer. However, the
current understanding on the molecular mechanisms of
c e rvi c a l  c a n c e r  m e t a s t as i s  i s  u n c l e a r .  I n  t h i s  s t u d y ,  w e
demonstrated that VEGF-C accelerated cervical cancer
metastasis by directly driving cancer cell migration and
invasion. These processes were closely related to the
effects of VEGF-C on moesin expression and activation
through RhoA/ROCK-2 signaling pathway. To our
knowledge, this is the first time reporting that moesin is
the target protein of VEGF-C and responsible for cervical
cancer metastasis.
Tumor metastasis is a complex process. A number of
cellular alterations occur as cancer cell spread to lymph
nodes and distant organs, including cellular transforma-
tion and tumor growth, angiogenesis and lymphangio-
genesis. VEGF-C, the dimeric glycoprotein belonging to
VEGF family of cytokines, plays critical role in a most of
aggressive tumors. Indeed, the elevated level of serum
VEGF-C has been found in patients with breast cancer
[22], lung cancer [23] and cervical cancer [8] and it
appears to be a unique marker for an early diagnosis of
cancer metastasis. Moreover, increased VEGF-C mRNA
expression in tumor tissues correlates positively with
lymphatic metastasis and poor prognosis [24-26].
VEGF-C is mainly produced by tumor and stromal cells
and it induces lymphangiogenesis that promotes the
growth and metastasis of neoplasms. These biological
effects are predominantly elicited by the activation of
VEGF-C specific receptor Flt-4 [27,28]. It has been pro-
posed that Flt-4 is restricted to be expressed on the lym-
Figure 4 VEGF-C activated moesin through RhoA/ROCK-2 pathway. (A-B) SiHa cells were treated with VEGF-C (100 ng/mL) for 48 h in the pres-
ence or absence of the ROCK-2 inhibitor, Y-27632 (Y - 10 μM) and moesin and phosphorylated moesin were assayed with western analysis. β-actin 
was used as the loading control. ** = P < 0.01 vs. corresponding control; ## = P < 0.01 vs VEGF-C 48 h. (C-D) SiHa cells were either mock-transfected 
(-Mock) or exposed to constitutively active or dominant-negative RhoA (- RhoA CA or - RhoA DN). Cells were then treated with VEGF-C (100 ng/mL) 
for 48 h and wild type and P-moesin were analyzed. ** = P < 0.01 vs. mock-transfected control; ## = P < 0.01 vs VEGF-C in mock or RhoA CA transfected 
group, or RhoA CA transfected alone. † = P < 0.05 vs. total RhoA in mock control; †† = P < 0.01 vs. total RhoA in mock control. All the above experiments 
were performed in triplicates and representative images are shown.
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phatic endothelium and tumor blood vessels [29].
However, recent studies have indicated that Flt-4 is also
expressed in a variety of human malignancies [28], indi-
cating that VEGF-C may affect cancer development and
progression by direct effects on tumor cells. In agree-
ment, we found that VEGF-C/Flt-4 axis drove cervical
cancer cell horizontal migration and three-dimensional
invasion into matrices, which are consistent with limited
reports that VEGF-C directly stimulated the motility of
other types of cancer cells [10,30,31], confirming that in
addition to the regulatory actions on lymphangiogenesis,
VEGF-C can promote tumor cell metastasis by directly
triggering cell migration and invasion in an autocrine
fashion.
While a lot is known on the molecular mechanisms of
VEGF-C on lymphangiogenesis [32], little information is
available on VEGF-C's direct impact on tumor cell motil-
ity. Reorganization of the actin cytoskeleton is the pri-
mary mechanism of cell motility and is essential for most
types of cell migration [33]. For example, our previous
studies have demonstrated that actin cytoskeleton
remodelling is the initial process for breast cancer metas-
tasis [14,34,35]. In this work, we indicated that VEGF-C
provoked actin fibers rearrangement in cervical cancer
cells and increased the formation of specialized mem-
brane structures, which may interact with the extra-cellu-
lar matrix and with nearby cells, thus allowing the tumor
cells to achieve locomotion. In analogy to our study, it's
a l s o  r e p o r t e d  b y  o t h e r  g r o u p s  t h a t  V E G F  o r  V E G F - C
induced actin reorganization and cell shape change in
vascular endothelial cells, leading to the sprouts of
endothelial cells [36,37].
Moesin, a member of the ERM family, is an actin-bind-
ing protein that plays a imperial role in cell motility by
linking the actin cytoskeleton to a variety of membrane-
anchoring proteins [38,39]. When activated through
phosphorylation of Thr558, moesin induces actin de-
polymerization and re-assembly toward the cell mem-
brane edge, being responsible for the formation of corti-
cal actin complexes. Our data showed that VEGF-C up-
regulated moesin expression and phosphorylation and
the silencing of moesin abolished VEGF-C's impact on
actin rearrangement, indicating that moesin is the target
protein for VEGF-C and the key mediator for actin
cytoskeleton remodelling. This may be strong evidence to
understand the mechanism that high moesin expression
correlates with lymph node metastasis. Actually, high
expression of ERM proteins has been identified as the
prognostic markers in clinical cancers [40] and the
expression pattern of moesin can be regarded as an inde-
pendent prognostic factor in patients with oral squamous
cell carcinoma [41]. Therefore, moesin expression may
serve as a potential marker for cervical cancer metastasis,
which need be further clinically investigated.
As previously reported [21,42,43], RhoA is a crucial
mediator conveying the upstream signaling evoked by
various factors to its downstream target ROCK-2, which
is a known activator of ERM proteins. In this study, we
showed that VEGF-C increased RhoA/ROCK-2 expres-
sion and activities. Moreover, the use of RhoA dominant
Figure 5 ROCK-2 silencing blocked VEGF-C effect on moesin activation. (A-B) Cells were exposed to VEGF-C (100 ng/mL) after transfection with 
100 nM target siRNA for ROCK-2 or scrambled siRNA for 48 h. Cell contents of wild-type or phosphorylated moesin are shown ** = P < 0.01 vs. corre-
sponding scrambled siRNA control; ## = P < 0.01 vs VEGF-C in scrambled siRNA group; †† = P < 0.01 vs. ROCK-2 in scrambled siRNA control. The ex-
periment was performed in triplicates and representative images are shown.
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negative construct or the inhibitor of ROCK-2 blocked
VEGF-C-enhanced moesin expression and phosphoryla-
tion, implying that RhoA/ROCK-2 represents the link
between VEGF-C and the activation of moesin. Indeed,
the significance of RhoA/ROCK-2 in VEGF signalling has
been displayed in endothelial cells, where RhoA/ROCK-2
mediates VEGF functions on microvascular permeability
[44], endothelial migration and angiogenesis [45]. More
importantly, the overexpression of RhoA is often
observed in clinical cancers [46] and it has been repeat-
edly identified as a gene associated with metastasis
[47,48]. These findings may partly be elucidated by our
data that RhoA/ROCK-2 was able to activate moesin and
finally led to enhanced cell motility. However, it should be
pointed out that our data is mainly obtained from in vitro
experiments. Whether the linkage between VEGF-C,
RhoA/ROCK-2 and moesin exists and functions in vivo
as we expected remains obscure. Our future studies will
be aimed to further define this issue and one possible way
is to suppress these proteins expression respectively with
effective approaches, such as siRNA gene therapy in cer-
Figure 6 RhoA/ROCK-2/moesin cascade was involved in VEGF-C-enhanced cell migration and invasion. (A-B) Cells were treated with VEGF-C 
(100 ng/mL) for 48 h after transfection with scrambled siRNA, moesin siRNA or ROCK-2 siRNA. The upper black lines indicate the starting line and the 
lower black lines indicate the mean migration distance. Cell migration was assayed and the migration cell numbers from the starting line are expressed 
as mean ± SD. ** = P < 0.01 vs. scrambled siRNA control; ## = P < 0.01 vs. VEGF-C in scrambled siRNA group. (C) Cells were treated with VEGF-C (100 
ng/mL) for 48 h after transfection with scrambled siRNA, moesin siRNA or ROCK-2 siRNA. Cell invasion was assayed using invasion chambers and in-
vasion indexes were shown. The experiments were performed in triplicates. ** = P < 0.01 vs. scrambled siRNA control; ## = P < 0.01 vs. VEGF-C in scram-
bled siRNA group.
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vical cancer mice model and then their relationship and
functions in cancer metastasis will be elucidated.
VEGF-C-enhanced migration and invasion of SiHa cell
is markedly inhibited by moesin or ROCK-2 specific siR-
NAs, suggesting that RhoA/ROCK-2/moesin cascade
plays an important role in these processes. Notwithstand-
ing, this is not the exclusive way that VEGF-C promotes
cancer cell motility. For example, it has been shown that
VEGF or VEGF-C promoted cancer cell metastasis by up-
regulation of integrin αvβ6 expression or of the neural
cell adhesion molecule contactin-1 through divergent cel-
lular signalings [10,31]. Moreover, other members of
ERM family, such as ezrin, function similarly as moesin in
cancer cells. Therefore, further efforts should focus on
the exact function of these proteins involving cervical
cancer metastasis.
Conclusion
Taken together, we demonstrated that VEGF-C activated
RhoA/ROCK-2/moesin cascade in cervical cancer cells,
leading to the accelerated cancer cell migration and inva-
sion. Genes and proteins within this signaling pathway
may be the potential targets to develop therapeutic strat-
egy for patients suffering from advanced cervical cancer.
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